A Bundled Intervention to End Opioid Overdoses
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age19+
SponsorUniversity of Alabama at Birmingham
About this trial
Opioid overdose deaths have reached historically high records in the United States and are particularly concentrated among patients after emergency department (ED) discharge. Evidence-based treatment modules to reduce repeat opioid overdose and mortality are lacking in this patient population. A bundled intervention is proposed, including telehealth, peer support specialist, buprenorphine, and linkage for definitive care, that is designed to increase treatment uptake in this patient population post-ED discharge, reduce repeat opioid overdoses, and end overdose deaths.
Eligibility criteria
Qualifiers
discharged from the ED and inpatient settings at the UAB hospital
19 years or older (the age of majority in Alabama);
diagnosis of OUD and experiencing opioid overdose in the last 12 months;
prescribed buprenorphine in the ED and willing to continue buprenorphine post-ED discharge;
Disqualifiers
living in a restricted environment (e.g., prison or jail facility, etc.);
currently enrolled in other clinical studies;
anticipated to take other prescribed opioids except buprenorphine for a medical condition longer than three months;
known allergic reaction to buprenorphine;
Trial design
Treatments tested in this trial
- Bundled intervention (Experimental)
- control group
- Buprenorphine (Experimental)
- Scheduled Peer Support Specialist (Experimental)
- Telemedicine Buprenorphine Treatment
Treatment groups
160 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Alabama at Birmingham
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov